The long term objective of these studies is to develop genetically defined systems for targeting gene expression to the prostate of transgenic mice based on regulatory elements of genes, viral or cellular in origin, that previously have been shown to be expressed in the various cell-types of the prostate. Since a major focus of the SPORE Molecular Mechanisms Group (SMMG) is to initiate perturbation analysis experiments to facilitate direct characterization of the molecular and cellular mechanisms governing transformation of the differentiating prostate in vivo, the studies in this proposal will provide SPORE investigators with vectors to direct aberrant oncogene- or tumor suppressor gene expression to the prostate in transgenic mice. The rationale for developing vectors exhibiting unique prostate- specific patterns of temporal and spatial expression and hormonal regulation is that the timing and level of targeted gene expression in the appropriate mesenchymal and epithelial cell types may influence the progression of prostatic disease. Initial studies will evaluate the efficacy of genomic fragments derived from the 5' flanking regions of the rat probasin (PB), seminal vesicle secretory II protein (SVSII) and human prostate specific antigen (PSA) genes, respectively, to direct prostate- specific expression of the bacterial chloramphenicol acetyltransferase (CAT) reporter gene in six week old transgenic mice. Depending on the outcome of these experiments, transgenic mice will be generated with constructs bearing the PB, SVSII or PSA promoters fused to a modified bacterial beta-galactosidase gene, pnlacF, to more carefully characterize the temporal, spatial and hormonal regulation of transgene expression. Parallel studies will place pnlacF under the transcriptional control of a minimal promoter fused to """"""""upstream activation sequences"""""""" (UAS; =GAL4 binding sites) to generate """"""""responder"""""""" lines of mice that will subsequently be mated with separate transactivator mice harboring a MMTV-LTR-GAL4 transgene. The temporal and spatial expression patterns of the activated pnlacF transgene will be characterized in the """"""""bigenic"""""""" offspring. Since transgenes normally remain quiescent in responder lines, the bigenic system overcomes breeding problems associated with male sterility that may occur as a consequence of activated transgene expression in the prostate. Hence, PB-, SVSII- and PSA-driven bigenic systems will also be developed. therefore, this project will facilitate the establishment of suitable animal models that will be used to identify biological factors involved in the progression of prostate cancer with the longterm goal of using these models for the development and testing of medical therapies for the prevention of such progression in collaboration with other SPORE investigators.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA058204-02
Application #
3774027
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
2
Fiscal Year
1993
Total Cost
Indirect Cost
Name
Baylor College of Medicine
Department
Type
DUNS #
074615394
City
Houston
State
TX
Country
United States
Zip Code
77030
Olar, Adriana; He, Dandan; Florentin, Diego et al. (2014) Biological correlates of prostate cancer perineural invasion diameter. Hum Pathol 45:1365-9
Olar, Adriana; He, Dandan; Florentin, Diego et al. (2014) Biologic correlates and significance of axonogenesis in prostate cancer. Hum Pathol 45:1358-64
Sonpavde, Guru; Wang, Mingjun; Peterson, Leif E et al. (2014) HLA-restricted NY-ESO-1 peptide immunotherapy for metastatic castration resistant prostate cancer. Invest New Drugs 32:235-242
Nakka, Manjula; Agoulnik, Irina U; Weigel, Nancy L (2013) Targeted disruption of the p160 coactivator interface of androgen receptor (AR) selectively inhibits AR activity in both androgen-dependent and castration-resistant AR-expressing prostate cancer cells. Int J Biochem Cell Biol 45:763-72
Ding, Yi; He, Dandan; Florentin, Diego et al. (2013) Semaphorin 4F as a critical regulator of neuroepithelial interactions and a biomarker of aggressive prostate cancer. Clin Cancer Res 19:6101-11
Feng, Shu; Dakhova, Olga; Creighton, Chad J et al. (2013) Endocrine fibroblast growth factor FGF19 promotes prostate cancer progression. Cancer Res 73:2551-62
Yang, Feng; Zhang, Yongyou; Ressler, Steven J et al. (2013) FGFR1 is essential for prostate cancer progression and metastasis. Cancer Res 73:3716-24
Yang, Guang; Goltsov, Alexei A; Ren, Chengzhen et al. (2012) Caveolin-1 upregulation contributes to c-Myc-induced high-grade prostatic intraepithelial neoplasia and prostate cancer. Mol Cancer Res 10:218-29
Sonpavde, Guru; Thompson, Timothy C; Jain, Rajul K et al. (2011) GLIPR1 tumor suppressor gene expressed by adenoviral vector as neoadjuvant intraprostatic injection for localized intermediate or high-risk prostate cancer preceding radical prostatectomy. Clin Cancer Res 17:7174-82
Wang, Jianghua; Cai, Yi; Shao, Long-Jiang et al. (2011) Activation of NF-{kappa}B by TMPRSS2/ERG Fusion Isoforms through Toll-Like Receptor-4. Cancer Res 71:1325-33

Showing the most recent 10 out of 262 publications